Exocure Therapeutics
Exosome-based Cancer Therapy for Breast and Pancreatic Tumors
Company Overview
Snapshot
Founded in September 2025 by Reem Miari and Mizied Falah Mizied Falah, Exocure Therapeutics operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing innovative exosome-based cancer therapies.
Business overview
Exocure Therapeutics is a Health Tech & Life Sciences company specializing in the development of exosome-based cancer therapeutics. Its core technology involves using exosomes sourced from naturally cancer-resistant tissue to selectively target tumor pathways, minimizing harm to healthy cells. The company's lead program is focused on breast and pancreatic cancers, with an intravenously administered therapy designed for standalone use or in combination with existing oncology treatments. Exocure Therapeutics is also exploring scalable manufacturing using human cell lines and the future potential to engineer exosomes to deliver therapeutic cargo such as chemotherapeutics, RNA, or proteins for targeted delivery. The company operates within the Drugs Discovery & Development sector, targeting healthcare providers and laboratories.
Log in to access full profile ›Company Intelligence Q&A
- What is Exocure Therapeutics' primary focus?
- Exocure Therapeutics is focused on developing exosome-based cancer therapeutics designed to selectively target tumor pathways while reducing harm to healthy cells. Their lead program targets breast and pancreatic cancers.
- When was Exocure Therapeutics founded?
- Exocure Therapeutics was founded in September 2025.
- Who are the founders of Exocure Therapeutics?
- Exocure Therapeutics was co-founded by Reem Miari, who serves as CEO, and Mizied Falah Mizied Falah, who is the CSO.
- What is the current stage of Exocure Therapeutics' product development?
- Exocure Therapeutics is currently in the R&D product stage, developing its exosome-based cancer therapies.
- Which markets does Exocure Therapeutics target?
- Exocure Therapeutics targets the healthcare and life sciences markets, specifically healthcare providers and laboratories.